Copyright © 2000 by the European Society of Cardiology.
Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction. A phase II dose escalation, randomized, double-blind study
a Thoraxcenter and Cardialysis, Rotterdam, The Netherlands
b Maria Ziekenhuis, Tilburg, The Netherlands
c St. Elisabeth Ziekenhuis, Tilburg, The Netherlands
d Krankenhaus Dresden-Friedrichstadt, Dresden, Germany
e Medisch Spectrum Twente, Enschede, The Netherlands
f Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
g Schering-Plough Research, Kenilworth, USA
h Karl L. Neuhaus, Stadtische Kliniken, Kassel, Germany
Received September 15, 1999; accepted December 1, 1999
Abstract
Aims Thrombolytic therapy restores coronary patency in patients with acute myocardial infarction, although normal perfusion (TIMI 3 flow) is not achieved in all patients. In an attempt to improve TIMI 3 flow, a combination of full-dose streptokinase, aspirin and escalating dosages of a platelet glycoprotein IIb/IIIa receptor blocker, eptifibatide, vs placebo were tested.
Methods and Results A bolus of 180µg.kg–1of eptifibatide was administered in each group, followed by a 72h continuous infusion of 0·75 (44 patients), 1·33 (n=45) and 2·00µg.kg–1.min–1(n=30); 62 patients received placebo. Normal perfusion (TIMI 3 flow) at 90min was observed in 31% of placebo patients compared to 46, 42 and 45% in the ascending eptifibatide groups (44% for combined eptifibatide groups, P=0·07). Patency (TIMI 2 and 3 flow combined) increased from 61% (placebo) to 78% for the combined eptifibatide groups (P=0·02). Reocclusion was infrequent. No differences were observed in TIMI flow grades among eptifibatide groups. Major and minor bleeding was increased and occurred mainly at the arterial puncture site.
Conclusion A combination of full dose streptokinase with different eptifibatide regimens enhanced coronary perfusion, but bleeding risk was excessive. Additional trials are needed with different dosage regimens to determine the optimal combination of fibrinolytic agents and platelet glycoprotein IIb/IIIa receptor blockers.
Key Words: Myocardial infarction, platelet aggregation inhibitors, thrombolysis, angiography, streptokinase, eptifibatide
f1 Correspondence: Prof. Maarten L. Simoons, Thoraxcenter, Bd 434, Academisch Ziekenhuis Dijkzigt, Dr. Molenwaterplain 40, 3015 GD, Rotterdam, The Netherlands.
References
- Kong DT, Calif RM, Miller DP. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 1998;98:2829–2835
[Abstract/Free Full Text] - Ronner E, Dykun Y, Van den Brand MJBM, Van der Wieken LR, Simoons ML. Platelet glycoprotein IIb/IIIa receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Eur Heart J. 1998;19:1608–1616
[Free Full Text] - Simoons ML, de Boer MJ, van den Brand MJ. Randomized trial of a glycoprotein IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994;89:596–603
[Abstract/Free Full Text] - Lancet. 1997;349:1429–1435[CrossRef][Web of Science][Medline]
- N Engl J Med. 1994;330:956–961
[Abstract/Free Full Text] - N Engl J Med. 1997;336:1689–1696
[Abstract/Free Full Text] - Brener SJ, Barr LA, Burchenal JEB. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 1998;98:734–741
[Abstract/Free Full Text] - Lancet. 1998;352:87–92[Web of Science][Medline]
- Gibson MC, Goel M, Cohen DJ. Six-month angiographic and clinical followup of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. J Am Coll Cardiol. 1998;32:28–34
[Abstract/Free Full Text] - Lancet. 1997;349:1422–1428[CrossRef][Web of Science][Medline]
- Song A, Scarborough RM, Phillips DR, Adelman B, Strony J. Eptifibatide enhances fibrinolysis and prevents acute arterial reoclusion following thrombolysis in a canine anodal current model with high-grade stenosis (Abstr). Circulation. 1992;86:I-410
- Gold HK, Coller BS, Yasuda T. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet glycoprotein IIb/IIIa antibody in a canine preparation. Circulation. 1988;77:670–677
[Abstract/Free Full Text] - Yasuda T, Gold HK, Leinbach RC. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet glycoprotein IIb/IIIa antibody. J Am Coll Cardiol. 1990;16:1728–1735[Abstract]
- Moliterno DJ, Topol EJ. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Thromb Haemost. 1997;78:214–219[Web of Science][Medline]
- Ohman EM, Kleiman NS, Gacioch G. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation. 1997;95:846–854
[Abstract/Free Full Text] - N Engl J Med. 1993;329:1615–1622
[Abstract/Free Full Text] - N Engl Med. 1985;312:932–936[Medline]
- Simoons ML, Maggioni AP, Knatterud G. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet. 1993;342:1523–1528[CrossRef][Web of Science][Medline]
- N Engl J Med. 1998;339:436–443
[Abstract/Free Full Text] - Eur Heart J. 1996;17:43–63
[Free Full Text] - Rao AK, Pratt C, Berke A. Thrombolysis in myocardial infarction (TIMI) trial—phase 1: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1–11[Abstract]
- Schroder R, Dissman R, Brüggemann T. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol. 1994;24:389–391
- Van't Hof AWJ, Liem A, De Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after succesfull reperfusion therapy for acute myocardial infarction. Lancet. 1997;350:615–619[CrossRef][Web of Science][Medline]
- Antman EM, Giugliano RP, Gibson MC. for the TIMI 14 investigators. Abciximab facilitates the rate and extent of thrombolysis. Results of the thrombolyis in myocardial infarction (TIMI) 14 trial. Circulation. 1999;99:2720–2732
[Abstract/Free Full Text] - Den Heier P, Vermeer F, Ambrosioni E. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation. 1998;98:2117–2125
[Abstract/Free Full Text] - Tebbe U, Michels R, Adgey AAJ. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS equivalence trial. Comparison trial of saruplase and streptokinase (COMASS) investigators. J Am Coll Cardiol. 1998;31:487–493
[Abstract/Free Full Text] - Benedict CR, Refino CJ, Keyt BA, Pakala R, Paoni NF, Thomas GR, Bennet WF. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation. 1995;92:3032–3040
[Abstract/Free Full Text] - J Am Coll Cardiol. 1998;32:2003–2010
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Part 5: Acute Coronary Syndromes Circulation, November 29, 2005; 112(22_suppl): III-55 - III-72. [Full Text] [PDF]
|
|
|
|
 |
|
 G. De Luca, H. Suryapranata, G. W. Stone, D. Antoniucci, J. E. Tcheng, F.-J. Neumann, F. Van de Werf, E. M. Antman, and E. J. Topol Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis of Randomized Trials JAMA, April 13, 2005; 293(14): 1759 - 1765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Giugliano, M. T. Roe, R. A. Harrington, C. M. Gibson, U. Zeymer, F. Van de Werf, K. W. Baran, H.-P. Hobbach, L. H. Woodlief, K. L. Hannan, et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: Results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic urial J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1251 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.L. Simoons, M. Krzeminska-Pakula, A. Alonso, S.G. Goodman, A. Kali, U. Loos, F. Gosset, V. Louer, and F. Bigonzi Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study Eur. Heart J., August 2, 2002; 23(16): 1282 - 1290. [Abstract] [PDF]
|
|
|
|
 |
|
 S. M. Inverso Combination Glycoprotein IIb/IIIa Receptor Antagonists With Thrombolytics in Acute Myocardial Infarction Journal of Pharmacy Practice, August 1, 2002; 15(4): 344 - 355. [Abstract] [PDF]
|
|
|
|
|
|
S. J. Brener, U. Zeymer, A. A. J. Adgey, T. R. Vrobel, S. G. Ellis, K.-L. Neuhaus, N. Juran, T. B. Ivanc, E. M. Ohman, J. Strony, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: The integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial J. Am. Coll. Cardiol., February 6, 2002; 39(3): 377 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Armstrong and D. Collen Fibrinolysis for Acute Myocardial Infarction : Current Status and New Horizons for Pharmacological Reperfusion, Part 2 Circulation, June 19, 2001; 103(24): 2987 - 2992. [Full Text] [PDF]
|
|
|
|
|
|
R. Wilcox Patency, perfusion, performance--the desirable triplets of combination thrombolytic therapy Eur. Heart J., September 2, 2000; 21(18): 1495 - 1497. [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||